MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan

References

• Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381(22):2135–2144. doi:10.1056/NEJMcp1816082
   PubMed Web of Science ®Google Scholar
• Kimura S, Roberts AW, Metcalf D, et al. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998;95(3):1195–1200. doi:10.1073/pnas.95.3.1195
   PubMed Web of Science ®Google Scholar
• Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998;92(1):4–10. doi:10.1182/blood.V92.1.4.413k38_4_10
   PubMed Web of Science ®Google Scholar
• Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 2006;20(15):2018–2023. doi:10.1101/gad.385606
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74(1):521–525. doi:10.1055/s-0038-1642732
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270), doi:10.1371/journal.pmed.0030270
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. rev. 4th ed. International Agency for Research on Cancer; 2017.
   Google Scholar
• Morishita S, Komatsu N, Kirito K, et al. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leukemia Res. 2011;35(12):1632–1636. doi:10.1016/j.leukres.2011.06.016
   PubMed Web of Science ®Google Scholar
• Misawa K, Yasuda H, Araki M, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol. 2018;107(6):673–680. doi:10.1007/s12185-018-2421-7
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120(6):1197–1201. doi:10.1182/blood-2012-01-403279
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. doi:10.1038/s41375-018-0077-1
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–5133. doi:10.1182/blood-2012-07-444067
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369. doi:10.1038/bcj.2015.94
   PubMed Web of Science ®Google Scholar
• Haider M, Gangat N, Lasho T, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91(4):390–394. doi:10.1002/ajh.24293
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48(3):452–458. doi:10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141–149. doi:10.1182/blood-2008-01-131664
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood. 2008;112(3):844–847. doi:10.1182/blood-2008-01-135897
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Haferlach C, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2009;94(1):141–144. doi:10.3324/haematol.13224
   PubMed Web of Science ®Google Scholar
• Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607–611. doi:10.3324/haematol.2010.034793
   PubMed Web of Science ®Google Scholar
• Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014;28(9):1912–1914. doi:10.1038/leu.2014.138
   PubMed Web of Science ®Google Scholar
• Okabe M, Yamaguchi H, Usuki K, et al. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leukemia Res. 2016;40:68–76. doi:10.1016/j.leukres.2015.11.002
   PubMed Web of Science ®Google Scholar
• Prejzner W, Mital A, Bieniaszewska M, et al. Clinical characteristics of essential thrombocythemia patients depend on the mutation status. Acta Haematol Pol. 2020;51(4):230–235. doi:10.2478/ahp-2020-0040
   Google Scholar
• Alvarez-Larran A, Angona A, Andrade-Campos M, et al. -Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish registry of essential thrombocythaemia. Br J Haematol. 2021;192(6):988–996. doi:10.1111/bjh.16988
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Nagaharu K, Ohishi K, et al. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia. Int J Hematol. 2021;113(5):618–621. doi:10.1007/s12185-021-03134-6
   PubMed Web of Science ®Google Scholar
• Loscocco GG, Guglielmelli P, Gangat N, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. Am J Hematol. 2021;96(11):1472–1480. doi:10.1002/ajh.26305
   PubMed Web of Science ®Google Scholar
• Yang E, Wang M, Wang Z, et al. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis. Ann Hematol. 2021;100(11):2699–2706. doi:10.1007/s00277-021-04617-6
   PubMed Web of Science ®Google Scholar
• Haider M, Elala YC, Gangat N, et al. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6(10):e487. doi:10.1038/bcj.2016.98
   PubMedGoogle Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790. doi:10.1056/NEJMoa051113
   PubMed Web of Science ®Google Scholar
• Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436). doi:10.1126/scitranslmed.aan829
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Plo I, Marty C, et al. The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Expert Rev Hematol. 2019;12(6):437–448. doi:10.1080/17474086.2019.1617129
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–4781. doi:10.1182/blood-2013-01-478891
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Ancochea A, García M, et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166(6):911–919. doi:10.1111/bjh.12990
   PubMed Web of Science ®Google Scholar